Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Renin-Angiotensin Signalling and Blood Pressure: Study Summary

Previous related pageVitamin D, Renin-Angiotensin Signalling and Blood Pressure: Full StudyNext related pageVitamin D, Renin-Angiotensin Signalling and Blood Pressure: Full Study
Study at a glance

Can vitamin D affect hormone signals that help control blood pressure?

Renin starts a chain of hormone signals that can narrow blood vessels and affect fluid balance. Researchers tested whether vitamin D signals control this process in mice and cells. A separate trial asked whether vitamin D3 supplements lower blood pressure in older people. A change in one chain of processes in the body does not guarantee a change in blood pressure.

What did the mouse and cell experiments show about renin?

Mice without vitamin D receptors throughout the body had higher renin gene activity, higher angiotensin II, a hormone in this pathway, and higher blood pressure. A medicine that blocks the pathway removed the pressure difference in a small experiment. Renin stayed high after low calcium was corrected, although another hormone remained high. Active vitamin D reduced renin gene activity in mice and engineered mouse cells. Removing a receptor is not the same as having a modestly low vitamin D blood result.

Did vitamin D3 lower blood pressure in older people?

VitDISH assigned 159 people aged 70 or older with raised systolic pressure, the top blood-pressure number, to vitamin D3 or placebo. Treatment was given every three months for a year. Most already took blood-pressure medicines. Vitamin D blood levels rose, but the trial found no clear reduction in blood pressure or overall benefit in the vessel tests. The uncertainty allowed for some lowering or raising of pressure, rather than proving exactly no effect.

Do these findings establish vitamin D3 as a blood-pressure treatment?

The trial did not measure renin or angiotensin II, so it could not directly disprove the laboratory mechanism. It tested one treatment schedule in a selected older population and does not settle every age group or daily-dose approach. Exploratory differences between groups taking different medicines did not establish who benefits. The evidence does not establish vitamin D3 as a blood-pressure treatment or show fewer heart and circulation problems.

Read the full article below ↓

Vitamin D signalling can reduce renin expression in mouse and cell experiments, but this does not establish that vitamin D supplements lower human blood pressure. A placebo-controlled trial in older people with isolated systolic hypertension found no clear pressure-lowering benefit from intermittent vitamin D3. The experimental and clinical findings answer different questions. For the detailed methods and appraisal, read Vitamin D, Renin-Angiotensin Signalling and Blood Pressure: Full Study.

Why renin matters

Renin starts a hormone cascade that generates angiotensin II, which can narrow vessels and influence fluid balance. The kidneys provide this hormonal setting, while vascular tone describes one component of resistance to blood flow. Pressure depends on several interacting systems, so a change in one molecular pathway need not produce a predictable change in the whole circulation.

What the mouse experiments showed

Li and colleagues studied mice lacking vitamin D receptors throughout the body. Renal renin messenger RNA was more than threefold higher and circulating angiotensin II more than 2.5-fold higher than in wild-type mice. Systolic and diastolic pressures, measured under anaesthesia, were more than 20 mm Hg higher. The genotype difference was no longer apparent after a small captopril experiment, supporting involvement of the renin-angiotensin pathway.

Renin remained elevated in young mice before low calcium developed and after a mineral-rich diet corrected adult blood calcium. This argues against hypocalcaemia as the sole explanation. Parathyroid hormone (PTH) remained high, however, so its contribution in living animals was not fully excluded. Salt loading and water deprivation still changed renin in expected directions; receptor loss altered regulation without abolishing every feedback response.

Calcitriol, the active vitamin D hormone, reduced renal renin expression in wild-type mice. In engineered mouse kidney cells, receptor expression enabled strong suppression of renin and its promoter activity. These findings support a transcriptional mechanism. They do not establish a nutritional dose for humans, and global receptor deletion is a much larger biological change than a modestly low vitamin D blood result.

What VitDISH tested

VitDISH assigned 159 people aged at least 70 to cholecalciferol or placebo: 80 and 79 participants respectively. All were white and lived in one Scottish health-board area. Mean age was about 77, baseline office pressure approximately 163/78 mm Hg, and mean 25-hydroxyvitamin D 18 ng/mL. Participants took 100,000 IU every three months for one year, with masked treatment and concealed central allocation.

The prespecified primary comparison was office pressure at three months. Most participants already took antihypertensive medication. Vitamin D status rose and observed-dose adherence was high; 76 versus 74 attended three months, and 73 versus 69 attended twelve months. Raising the measured status marker therefore did not guarantee a corresponding functional response.

The result and its limits

The primary-results text reports a three-month systolic difference of −0.7 mm Hg, with a 95% confidence interval from −5.2 to 3.8. This includes both benefit and harm and provides no clear evidence of lowering pressure. Across follow-up, the systolic estimate was +1 mm Hg, with an interval from −2 to 4. Ambulatory pressure and the overall endothelial-dilation and arterial-stiffness measurements also showed no clear benefit.

An exploratory interaction with existing renin-angiotensin-blocking medicines does not establish a responsive subgroup. The trial did not measure renin or angiotensin II as reported outcomes, so it cannot directly refute the mouse mechanism. It also cannot settle every age group, daily-dose regimen or severe-deficiency setting. Supplementary methods and detailed adverse-event categories were unavailable for independent review; the main paper and registration support the conclusions presented here.

What this means

A receptor-dependent renin mechanism and a null supplementation result can both be valid. The evidence supports biological plausibility but does not establish vitamin D3 as a blood-pressure treatment or show fewer cardiovascular events. Interpreting the studies requires keeping the model, exposure and measured outcome together.

Scientific sources

Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. Journal of Clinical Investigation. 2002;110(2):229-238. DOI: 10.1172/JCI15219. PMID: 12122115. Mouse and cell experiments; complete main paper, tables and figures examined.

Witham MD, Price RJG, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo MET. Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial. JAMA Internal Medicine. 2013;173(18):1672-1679. DOI: 10.1001/jamainternmed.2013.9043. PMID: 23939263. Randomised clinical trial; main paper, figures and tables examined. Supplementary eMethods and adverse-event eTable were not accessible.

University of Dundee; study investigator Miles Witham. Vitamin D for Isolated Systolic Hypertension (VitDISH). ISRCTN92186858. Registered 21 August 2008. DOI: 10.1186/ISRCTN92186858. Registration supplies prespecified outcomes and eligibility; it is a record of the same trial, not independent efficacy evidence.

Related reading

Original sources

Source

Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial

Published in JAMA Internal Medicine (2013).

Publication details

Witham MD, Price RJG, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo MET. Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial. JAMA Internal Medicine. 2013;173(18):1672-1679. DOI: 10.1001/jamainternmed.2013.9043. PMID: 23939263. Randomised clinical trial; main paper, figures and tables examined. Supplementary eMethods and adverse-event eTable were not accessible.

Read more →
Source

Vitamin D for Isolated Systolic Hypertension (VitDISH)

University of Dundee; study investigator Miles Witham.

Publication details

University of Dundee; study investigator Miles Witham. Vitamin D for Isolated Systolic Hypertension (VitDISH). ISRCTN92186858. Registered 21 August 2008. DOI: 10.1186/ISRCTN92186858. Registration supplies prespecified outcomes and eligibility; it is a record of the same trial, not independent efficacy evidence.

Read more →